前瞻性临床试验纳入的子宫内膜癌患者结局异质性
利用美国国家癌症数据库回顾性识别2004至2016年接受子宫切除术的子宫内膜癌患者,按GOG-249、PORTEC-3和GOG-258的入组标准划分队列,分析五年总生存率。共纳入89,133例符合任一试验入组标准的患者,按肿瘤特征分层后五年总生存率跨度很大。作者认为近期前瞻性辅助治疗试验纳入的是异质性队列,预期生存的差异可能导致研究把握度不足或结果误导。
要点
- 按GOG-249、PORTEC-3、GOG-258入组标准划分的队列,五年总生存率随肿瘤特征分层跨度很大。
- 符合GOG-249标准者五年总生存率59.9%-81.7%,PORTEC-3为40.2%-81.8%,GOG-258为17.5%-75.0%。
- 在子宫内膜样III期和IVA期及部分浆液性和透明细胞组织学中,放化疗较单纯化疗或放疗显著改善五年总生存率。
核心结论
- 近期子宫内膜癌辅助治疗前瞻性试验纳入的是异质性患者队列,按肿瘤特征分层后五年总生存率差异明显。
- 患者亚组预期五年总生存率的差异可能导致研究把握度不足或结果误导。
研究设计与样本
- 回顾性研究,使用美国国家癌症数据库识别2004至2016年接受子宫切除术的子宫内膜癌患者。
- 按GOG-249、PORTEC-3和GOG-258报告的入组标准定义各自队列。
- 共识别89,133例符合GOG-249、PORTEC-3或GOG-258入组标准的患者。
- 每个队列的五年总生存率按肿瘤特征和辅助治疗方案分层分析。
主要发现
- 按肿瘤特征分层且不考虑辅助治疗时,符合GOG-249入组标准者五年总生存率为59.9%-81.7%。
- 符合PORTEC-3入组标准者五年总生存率为40.2%-81.8%。
- 符合GOG-258入组标准者五年总生存率为17.5%-75.0%。
- 按辅助治疗方案分析亚组显示,对于子宫内膜样III期和IVA期疾病及部分浆液性和透明细胞组织学分期,放化疗较单纯化疗或放疗显著改善五年总生存率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess heterogeneity in five-year overall survival of patients with endometrial cancer using a large retrospective database with cohorts defined by recent prospective clinical trials. METHODS: The National Cancer Database was used to identify patients with endometrial cancer who underwent hysterectomy from 2004 to 2016. The reported inclusion criteria for GOG-249, PORTEC-3, and GOG-258 were used to define the respective cohorts. Five-year overall survival for each cohort was stratified by tumor characteristics and adjuvant therapy regimens. RESULTS: A total of 89,133 patients were identified who would have fulfilled the entry criteria to GOG-249, PORTEC-3, or GOG-258. When stratified by tumor characteristics, irrespective of adjuvant therapy, five-year overall survival ranged from 59.9%-81.7% for patients meeting GOG-249 inclusion criteria, 40.2%-81.8% for patients meeting PORTEC-3 inclusion criteria, and 17.5%-75.0% for those meeting GOG-258 inclusion criteria. Analysis of subgroups by adjuvant therapy regimen revealed significant improvement in five-year overall survival for chemoradiotherapy compared to chemotherapy or radiotherapy alone for endometroid stage III and stage IVA disease and for some stages of serous and clear cell histology. CONCLUSIONS: Recent prospective trials of adjuvant therapy for endometrial cancer have included heterogeneous cohorts of patients based on five-year overall survival rates when the populations are stratified by tumor characteristics. The variation in expected five-year overall survival for subsets of patients may result in underpowered studies or misleading results.
引用
- Boone RM, Praiss AM, Huang Y, et al. Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials. Gynecol Oncol. 2022. PMID: 36521351. doi:10.1016/j.ygyno.2022.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。